Abstract
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Current Neuropharmacology
Title:Serotonin2C Receptors and the Motor Control of Oral Activity
Volume: 11 Issue: 2
Author(s): Melanie Lagiere, Sylvia Navailles, Marion Bosc, Martin Guthrie and Philippe De Deurwaerdere
Affiliation:
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Abstract: Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Export Options
About this article
Cite this article as:
Lagiere Melanie, Navailles Sylvia, Bosc Marion, Guthrie Martin and Deurwaerdere De Philippe, Serotonin2C Receptors and the Motor Control of Oral Activity, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020003
DOI https://dx.doi.org/10.2174/1570159X11311020003 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Pharmacological Uses of the Plants Belonging to the Genus <i>Commiphora</i>
Cardiovascular & Hematological Agents in Medicinal Chemistry Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva
Current Pharmaceutical Design NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents
Recent Patents on Anti-Cancer Drug Discovery The Effects of Vitamin B in Depression
Current Medicinal Chemistry Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry COX-2 Signaling and Cancer: New Players in Old Arena
Current Drug Targets Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets The Prevention of Adverse Drug Reactions in Older Subjects
Current Drug Metabolism Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes
Current Drug Targets Evaluation of Antileishmanial Activity Employing Conventional and Solid Lipid Nanoparticles of Amphotericin B on Leishmania major In Vitro and In Vivo
Infectious Disorders - Drug Targets Discovery of Highly Selective Inhibitors of p38α
Current Topics in Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition The Effectiveness of Topical Anti-scarring Agents and a Novel Combined Process on Cutaneous Scar Management
Current Pharmaceutical Design Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Applications of Molecular Dynamics Simulations in Immunology: A Useful Computational Method in Aiding Vaccine Design
Current Proteomics